NCT02050529View on ClinicalTrials.gov

Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.

PHASE2CompletedINTERVENTIONAL

Enrollment

190

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

March 31, 2015

Conditions

Hypertension, Pregnancy InducedHydralazine Adverse ReactionPre-eclampsiaPre-eclampsia Superimposed Pre-existing Hypertension

Interventions

DRUG

Labetalol

Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.

DRUG

Hydralazine

Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.

Trial Locations (1)

74200

Civil Hospital Karachi, Karachi

All Listed Sponsors

lead

Dow University of Health Sciences

OTHER

NCT02050529 - Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients. | Biotech Hunter | Biotech Hunter